Active	Status	Sponsor type	Region	Phase	Filter
25 Active 9 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chow, Elaine
NCT05268237: Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus	Recruiting	1/2	15	RoW	Liraglutide, Placebo	Biolingus, Chinese University of Hong Kong	Diabete Type 2	05/24	07/24
NCT04964752: A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes	Not yet recruiting	N/A	144	NA	continuous glucose-monitoring, CGM	Lee's Pharmaceutical Limited, Powder (Guangzhou) Pharmaceuticals Limited, Powder Pharmaceuticals (HK) Co., Ltd	Diabetes	02/22	04/22
Choi, Joseph
N-MOmentum LT, NCT06180278: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)	Recruiting	4	30	Europe, US, RoW	Blood tests, Inebilizumab, UPLIZNA	Amgen	Neuromyelitis Optica Spectrum Disorder	06/28	06/28
NCT04697004: SMR Stemless Reverse Vs SMR Reverse Shoulder System	Recruiting	N/A	200	US	Investigational Arm: SMR Stemless Reverse, Control Arm: SMR Reverse Shoulder System	Limacorporate S.p.a, NAMSA	Arthroplasty, Replacement	03/26	03/26
Liu, Mandy
N-MOmentum LT, NCT06180278: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)	Recruiting	4	30	Europe, US, RoW	Blood tests, Inebilizumab, UPLIZNA	Amgen	Neuromyelitis Optica Spectrum Disorder	06/28	06/28